

Daiichi Sankyo in discussion with AZ for COVID-19 vaccine supply

02 July 2020 | News

Of a potential novel corona virus vaccine being developed by AstraZeneca and Oxford University



Japan based Daiichi Sankyo Company, Limited has announced its agreement to proceed with discussions with AstraZeneca for the stable supply in Japan of a potential novel corona virus vaccine being developed by AstraZeneca and Oxford University.

AstraZeneca has agreed to advance specific discussions with the Japanese government toward the introduction of the vaccine in Japan, and based on that agreement, Daiichi Sankyo has decided to advance discussions with AstraZeneca to formulate the vaccine, including vial filling, packaging, and storage in Japan.

Moreover, Daiichi Sankyo Biotech Co., Ltd., a subsidiary of Daiichi Sankyo, plans to receive the undiluted solution from AstraZeneca and then carry out the formulation procedures using the “New Influenza Vaccine Development and Production System Development Project” facilities.

In order to restore people’s peace of mind and safety by helping to end the COVID-19 pandemic as soon as possible, Daiichi Sankyo will promote the ongoing research and development of the Nafamostat Inhalation Formulation and mRNA vaccine as well as advance the necessary preparations for the stable supply of a vaccine in Japan in consultation with AstraZeneca.